These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 22827242)

  • 1. Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status.
    Korsholm KS; Andersen PL; Christensen D
    Expert Rev Vaccines; 2012 May; 11(5):561-77. PubMed ID: 22827242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
    Nordly P; Madsen HB; Nielsen HM; Foged C
    Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cationic liposomes as vaccine adjuvants.
    Christensen D; Korsholm KS; Andersen P; Agger EM
    Expert Rev Vaccines; 2011 Apr; 10(4):513-21. PubMed ID: 21506648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome-based cationic adjuvant formulations (CAF): past, present, and future.
    Christensen D; Agger EM; Andreasen LV; Kirby D; Andersen P; Perrie Y
    J Liposome Res; 2009; 19(1):2-11. PubMed ID: 19515003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cationic liposomes as vaccine adjuvants.
    Christensen D; Korsholm KS; Rosenkrands I; Lindenstrøm T; Andersen P; Agger EM
    Expert Rev Vaccines; 2007 Oct; 6(5):785-96. PubMed ID: 17931158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal vaccine delivery systems.
    Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
    Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cationic liposomes as adjuvants for influenza hemagglutinin: more than charge alone.
    Barnier Quer C; Elsharkawy A; Romeijn S; Kros A; Jiskoot W
    Eur J Pharm Biopharm; 2012 Jun; 81(2):294-302. PubMed ID: 22487055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposome-based delivery system for vaccine candidates: constructing an effective formulation.
    Giddam AK; Zaman M; Skwarczynski M; Toth I
    Nanomedicine (Lond); 2012 Dec; 7(12):1877-93. PubMed ID: 23249332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the adjuvant and cytotoxic effects of the positive charges and polymerization in liposomes.
    Gasparri J; Speroni L; Chiaramoni NS; del Valle Alonso S
    J Liposome Res; 2011 Jun; 21(2):124-33. PubMed ID: 20550461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response.
    Henriksen-Lacey M; Christensen D; Bramwell VW; Lindenstrøm T; Agger EM; Andersen P; Perrie Y
    J Control Release; 2010 Jul; 145(2):102-8. PubMed ID: 20381556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog.
    Christensen D; Henriksen-Lacey M; Kamath AT; Lindenstrøm T; Korsholm KS; Christensen JP; Rochat AF; Lambert PH; Andersen P; Siegrist CA; Perrie Y; Agger EM
    J Control Release; 2012 Jun; 160(3):468-76. PubMed ID: 22709414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mannosylated liposomes for targeted vaccines delivery.
    Vyas SP; Goyal AK; Khatri K
    Methods Mol Biol; 2010; 605():177-88. PubMed ID: 20072881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunological adjuvant and vaccine carrier properties of liposomes.
    Gregoriadis G
    J Drug Target; 1994; 2(5):351-6. PubMed ID: 7704478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposome fusogenicity and entrapment efficiency of antigen determine the Th1/Th2 bias of antigen-specific immune response.
    Brgles M; Habjanec L; Halassy B; Tomasić J
    Vaccine; 2009 Sep; 27(40):5435-42. PubMed ID: 19632317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal adjuvants: preparation and formulation with antigens.
    Haensler J
    Methods Mol Biol; 2010; 626():73-90. PubMed ID: 20099122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal adjuvants for human vaccines.
    Alving CR; Beck Z; Matyas GR; Rao M
    Expert Opin Drug Deliv; 2016 Jun; 13(6):807-16. PubMed ID: 26866300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis.
    Shargh VH; Jaafari MR; Khamesipour A; Jaafari I; Jalali SA; Abbasi A; Badiee A
    Vaccine; 2012 Jun; 30(26):3957-64. PubMed ID: 22465747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: effect of charge, fluidity and antigen-to-lipid ratio.
    Hamborg M; Rose F; Jorgensen L; Bjorklund K; Pedersen HB; Christensen D; Foged C
    Biochim Biophys Acta; 2014 Aug; 1838(8):2001-10. PubMed ID: 24769435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.
    Nordly P; Rose F; Christensen D; Nielsen HM; Andersen P; Agger EM; Foged C
    J Control Release; 2011 Mar; 150(3):307-17. PubMed ID: 21111765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.